SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after reporting stellar Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, demonstrating high efficacy and potential disease-modifying effects. This positive data, coupled with a major institutional investor significantly increasing its stake and an anticipated Investor Day, has ignited strong community discussion about its "best-in-class" potential, a potential re-rating, and a short squeeze.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its Mainnet recently went live and a partnership with Aplix for a Japan-regulated stablecoin was announced, alongside its inclusion in Coinbase's institutional index for perpetual futures. This has sparked a polarized community discussion, with proponents highlighting these fundamental advancements for long-term potential, while critics remain skeptical given the token's continued price performance.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is actively discussed following its recent financial results, which showed solid U.S. same-store sales growth and a 15% dividend increase, alongside reports of prominent hedge funds, including Warren Buffett's Berkshire Hathaway, increasing their positions. The community is debating if its "Hungry for MORE" strategy and market leadership can continue to drive growth amidst a mixed restaurant sector and concerns over valuation.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending as the community processes its solid Q4 earnings beat against conservative 2026 guidance, alongside significant M&A activity including the Arcellx acquisition and key patent settlements for its dominant HIV franchise. Investors are also closely watching developments in its oncology pipeline, such as recent Trodelvy trial results, amid discussions about the company's long-term growth trajectory in a volatile market.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following pivotal international approvals for its ANKTIVA cancer therapy in the EU and Saudi Arabia, complemented by robust revenue growth. The community is buzzing about the drug's global market expansion and potential as a chemotherapy-free cancer treatment, anticipating a substantial short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phoenix Motor Inc. (19% increase in followers)Anaheim, California-based Phoenix Motor makes electric buses and trucks for various service and government fleet markets.&nbsp;This year, the company drew considerable attention after reporting encouraging fiscal third-quarter results in February that showed revenue soaring by 1,557% to $4.77 million even as net losses widened.&nbsp;After posting these results, which were delayed earlier, it regained compliance with the Nasdaq listing.In February, the company established EdisonFuture International, a Hong Kong-based subsidiary focused on expanding its EV business globally, targeting markets in the Caribbean, South America, Europe, and Asia.&nbsp;For 2024, Phoenix Motor projects revenue of $30 million to $31 million, a tenfold increase from $3 million in 2023. It expects to turn profitable after reporting a net loss in the prior year,&nbsp;with revenue for fiscal year 2025 forecasted to be in the $40 million to $50 million range.Additionally, the company's board approved a $5 million share repurchase program last week.Phoenix Motor's stock has gained 9.5% this year.Chijet Motor Company Inc. (13% increase in followers)Chijet, a Chinese developer of next-generation electric vehicles, has not had any significant news catalysts this year.&nbsp;Last month, the company received a staff determination letter from Nasdaq, notifying Chijet of its impending delisting from the Nasdaq Global Market.&nbsp;The decision came after Chijet failed to regain compliance with the exchange's minimum market value requirements: $50 million for listed securities and $15 million for publicly held shares.During its listing on the Nasdaq in June 2023, Chijet said it has a pipeline of more than a dozen new vehicles and aims to launch its FB77, a pure electric sedan, and the R9 PHEV hybrid SUV in the coming years.The company had said that future models, including the FV20, FB21, and FB31, will span both commercial and passenger segments.Chijet's stock has lost over 20% this year.Zeekr Intelligent Technology Holding (10% increase in followers)Chinese electric vehicle maker Zeekr has been making headlines this year with strong monthly delivery numbers and reports of new premium launches.&nbsp;The Geely-owned automaker's own brand sales surged 86.9% year-over-year in February, and the recent Lynk &amp; Co acquisition boosted total deliveries.&nbsp;Zeekr is also set to unveil the ultra-luxury 9X Grand SUV this month in China, targeting high-end consumers and taking on brands like Mercedes-Benz and BMW.Zeekr stock has lost over 13% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Visitors check ZEEKR 7X cars displayed at the 46th Bangkok International Motor Show 2025 in Nonthaburi province on the outskirts of Bangkok, Thailand, on March 28, 2025. (Photo by Anusak Laowilas/NurPhoto via Getty Images)

Phoenix Motor, Chijet, Zeekr: Retail Traders Flocked To These 3 Auto Stocks The Most In Q1

Although companies such as Tesla, Rivian and legacy automakers such as Ford and GM have dominated headlines this year, these lesser known brands captivated Stocktwits users more in Q1 2025. 

Equity

These five automobile-linked stocks notched the biggest jump in retail following on Stocktwits in the week ended Feb. 14, 2025:WeRide Inc. (+460% jump in following)Chinese self-driving startup WeRide surged to a record high after an SEC filing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/wrd-stock-hits-record-high-on-nvidia-stake/ch5iISdRHD">revealed</a> that AI chip giant Nvidia had taken a stake, owning 1.7 million shares.&nbsp;According to The Fly, Morgan Stanley called the move a sign of growing investor enthusiasm for self-driving technology and the value of strategic alliances in the robotaxi space. The research firm has an 'Overweight' rating and a $23 price target on the stock, which is up 122% year-to-date (YTD).Phoenix Motor Inc. (+14% jump in following)Phoenix Motor regained Nasdaq compliance after resolving delays in its SEC filings, giving the stock a lift. Earlier in the week, the company posted fiscal third-quarter revenue of $4.8 million, up sharply from just $0.2 million a year earlier. It cited the successful integration of its transit segment and partnerships in AI and autonomous tech.&nbsp;Shares are up 25% YTD.Strattec Security Corporation (+8% jump in following)Auto security supplier Strattec continued its rally, likely fueled by strong earnings earlier in the month. Fiscal second-quarter net sales rose 9.6% to $129.9 million, beating estimates, driven by new program launches and rising volumes from key customers like GM and Ford. While sales to Stellantis lagged, demand was strong in North America, particularly from Hyundai.Shares are up nearly 19% YTD.Hesai Group (+5% jump in following)Lidar maker Hesai announced a deeper collaboration with Chinese EV giant BYD, providing lidar for more than 10 upcoming BYD models set for mass production in 2025. BYD, which sold over 4 million intelligent-driving-equipped vehicles last year, is integrating Hesai’s lidar into its next-gen “God’s Eye” ADAS system, expected to expand self-driving features across its lineup.&nbsp;Hesai’s stock is up over 29% YTD.Motorcar Parts of America (+2.5% jump in following)Motorcar Parts reported strong fiscal Q3 results as it swung to a profit, with revenue rising to $186.2 million from $171.9 million last year. CEO Selwyn Joffe highlighted the company’s leadership in the non-discretionary aftermarket parts sector and its focus on quality and customer service.&nbsp;Shares are up 24% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the WeRide, Inc. logo is displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Top 5 Auto Stocks That Had Retail Traders Revved Up Last Week

From AI giants taking a stake to earnings beats, these auto-linked stocks saw the biggest surge in new Stocktwits followers.

Phoenix Motor, Inc. designs, develops, manufactures, assembles, and integrates electric drive systems and light and medium duty electric vehicles, with an aim to reduce carbon intensity and greenhouse gas emissions. It operates under the brands Phoenix Motorcars, which is focused on commercial products including medium duty electric vehicles, chargers, and electric forklifts, and EdisonFuture, which intends to offer light-duty electric vehicles. The company was founded in 2003 and is headquartered in Anaheim, CA.

PEV
Phoenix Motor Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PEV News

PEV Phoenix Motor Inc